GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Consensus Recommendation of “Buy” from Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has been given an average recommendation of “Buy” by the seven ratings firms that are covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $14.20.

Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 price objective on shares of GeoVax Labs in a report on Thursday, February 27th.

Hedge Funds Weigh In On GeoVax Labs

Several institutional investors and hedge funds have recently made changes to their positions in the business. Northern Trust Corp purchased a new position in shares of GeoVax Labs in the fourth quarter worth $29,000. Virtu Financial LLC bought a new position in shares of GeoVax Labs during the third quarter valued at approximately $97,000. Citadel Advisors LLC purchased a new stake in GeoVax Labs in the fourth quarter worth $104,000. Finally, Geode Capital Management LLC boosted its holdings in GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares in the last quarter. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $1.54 on Friday. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18. The stock has a fifty day moving average of $1.85 and a 200 day moving average of $2.33.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.